Prospective, Multicenter Clinical Trial of Atorvastatin-Based Acute Graft-Versus-Host-Disease (aGVHD) Prophylaxis in Recipients of HLA-Matched Related Donor (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplantation (alloHCT)
Mehdi Hamadani(Medical College of Wisconsin), Abraham S. Kanate(HonorHealth), Carlos Arce‐Lara, Parameswaran Hari(Medical College of Wisconsin), Anita D’Souza, Jennifer Boyd(Medical College of Wisconsin), Wael Saber(Medical College of Wisconsin), Timothy S. Fenske(Medical College of Wisconsin), William R. Drobyski(Medical College of Wisconsin), J. Douglas Rizzo, Michael Craig(Edith Cowan University), Marcelo C. Pasquini(Cleveland Clinic), Mary M. Horowitz(Medical College of Wisconsin), Pamela Bunner(West Virginia University), Kwang Woo Ahn(Medical College of Wisconsin), Alexis Visotcky(Medical College of Wisconsin), Aaron Cumpston(West Virginia University Hospitals)
Cited by 1
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Solid Cancers after Bone Marrow Transplantation
|New England Journal of Medicine|1997|968